INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 08, 2004 |
VP Clinical Programs
Trans History: 37
|
VP Clinical Programs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 500 | -- | -- |
| Oct 08, 2004 |
VP Clinical Programs
Trans History: 37
|
VP Clinical Programs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,626 | -- | -- |
| May 03, 2004 |
Director
Trans History: 381
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 5,000 | $13.05 | -- |
| Mar 01, 2004 |
Director
Trans History: 466
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,000 | -- | -- |
| Mar 01, 2004 |
Director
Trans History: 368
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 600 | $14.94 | -- |
| Mar 01, 2004 |
Director
Trans History: 368
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 600 | -- | -- |
| Mar 01, 2004 |
Director
Trans History: 326
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,000 | -- | -- |
| Feb 02, 2004 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 500 | -- | -- |
| Jan 04, 2004 |
Director, Chief Exec Officer & President
Trans History: 422
|
Director, Chief Exec Officer & President | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,990 | -- | -- |
| Oct 08, 2003 |
Director
Trans History: 381
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 3,000 | $14.51 | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.